Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > TOP STORIES
TOP STORIES
-
ORGANIZATION CES Waivers Could Slow Biosimilar Uptake without Better Communication: Industry
July 23, 2026
-
REGULATORY Japan Sees Limited Impact from Planned US Tariffs on Generics
July 23, 2026
-
REGULATORY Ishin Lawmaker Seeks Full Chuikyo Seat for Industry, but with Fiscal Responsibility
July 22, 2026
-
BUSINESS Sanofi Delays Japan Launch of Efluelda by One Year, Defers NIP Rollout
July 22, 2026
-
REGULATORY Japan OKs Honebuto, Growth Strategy with Patented Drug Market Goals
July 21, 2026
-
REGULATORY Takeda’s Oveporexton, Rhythm’s Imcivree Up for Japan Panel Review Aug. 3
July 21, 2026
-
ORGANIZATION JPMA, PhRMA Raise Alarm over Generic Approvals During Patent Extensions
July 17, 2026
-
REGULATORY Govt Set to Amend Honebuto Draft over Inflation, MFN Language
July 16, 2026
-
REGULATORY HHS Report Puts Japan’s Drug Innovation Financing Well Behind US
July 15, 2026
-
BUSINESS iPark Eyes Shared AI Platform to Keep Japan in Global Drug Discovery Race
July 14, 2026
-
REGULATORY Japan Panel to Review Brinsupri, Hyrnuo, Inlexzo, GSK’s Hep B Med on July 27
July 14, 2026
-
REGULATORY CEA Review Group Debates Comparator Technologies, ICER Uncertainty
July 14, 2026
-
COMMENTARY A Turning Point for Pharma? Chuikyo Reform Could Open Door to Greater Industry Role
July 13, 2026
-
REGULATORY Japan to Set Up Subgroup to Flesh Out Pharma Investment Roadmap: PM
July 13, 2026
-
BUSINESS Marubeni Pharma Seeks New Growth Drivers to Hit FY2035 Sales Goal
July 10, 2026
-
BUSINESS Women Hold Nearly 1/4 of Leadership Roles at Japan’s Listed Pharmas and Wholesalers
July 10, 2026
-
ORGANIZATION FIRM Backs Growth Roadmap, Expects Better Investment Climate
July 10, 2026
-
REGULATORY MHLW Study Group Proposes Six Options to Put Japan’s Patent Linkage System into Law
July 9, 2026
-
REGULATORY Chuikyo Kicks Off Debate on FY2027 Off-Year Drug Price Revision
July 9, 2026
-
REGULATORY Boehringer’s Big-Seller Hopeful Jascayd Set for Listing, Haihe’s Haizexin Too
July 9, 2026
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…